ERCC1-XPF缺陷可预测上皮性卵巢癌对奥拉帕利诱导的合成致死及铂类敏感性
研究在331例诺丁汉大学医院治疗的卵巢癌患者中评估ERCC1、XPF和PARP1蛋白表达与临床病理特征及生存的相关性,并在A2780(铂敏感)和A2780cis(铂耐药)细胞系中敲低ERCC1和XPF后检测铂类敏感性及奥拉帕利诱导的合成致死。结果显示低ERCC1与改善的无进展生存期显著相关,低ERCC1/低XPF或低ERCC1/低PARP1肿瘤相比高表达组PFS更好;临床前敲低ERCC1或XPF不仅增加铂类敏感性还增加奥拉帕利毒性。结论提示低ERCC1不仅是铂类敏感性的预测因子,也是卵巢癌中奥拉帕利诱导合成致死的有前景的生物标志物。
要点
- 低ERCC1与卵巢癌患者改善的无进展生存期显著相关(单因素p=0.001,多因素p=0.002)。
- 低ERCC1/低XPF(p=0.003)或低ERCC1/低PARP1(p=0.0001)肿瘤相较高表达组PFS更好。
- 临床前敲低ERCC1或XPF增加铂类敏感性并增加奥拉帕利毒性,伴DNA双链断裂积累、细胞周期阻滞和凋亡增加。
核心结论
- 数据表明低ERCC1不仅是铂类敏感性的预测因子,也是卵巢癌中奥拉帕利诱导合成致死的有前景的生物标志物。
研究设计与样本
- 在诺丁汉大学医院治疗的331例患者肿瘤队列中评估ERCC1、XPF和PARP1蛋白表达,并与临床病理特征及生存进行相关性分析。
- 临床前在A2780(铂敏感)和A2780cis(铂耐药)卵巢癌细胞系中敲低ERCC1和XPF,检测铂类敏感性及奥拉帕利诱导的合成致死。
主要发现
- 低ERCC1与卵巢癌患者改善的无进展生存期显著相关,单因素分析p=0.001,多因素分析p=0.002。
- 低ERCC1/低XPF肿瘤(p=0.003)或低ERCC1/低PARP1肿瘤(p=0.0001)相比高ERCC1/高XPF或高ERCC1/高PARP1肿瘤与更好的PFS相关。
- 临床前敲低ERCC1或XPF不仅增加铂类敏感性,还增加奥拉帕利治疗的毒性。
- 敏感性增加与DNA双链断裂积累、细胞周期阻滞和凋亡增加相关。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: PARP inhibitor maintenance therapy in platinum sensitive sporadic ovarian cancers improves progression free survival. However, biomarker for synthetic lethality in platinum sensitive sporadic disease is yet to be defined. ERCC1-XPF heterodimer is a key player in nucleotide excision repair (NER) involved in the repair of platinum induced DNA damage. In the current study, we tested whether ERCC1-XPF deficiency would predict synthetic lethality to the PARP inhibitor Olaparib and platinum sensitivity in ovarian cancers. METHODS: ERCC1, XPF and PARP1 protein expression was evaluated in tumors from a cohort of 331 patients treated at Nottingham University Hospitals and correlated to clinicopathological features and survival. Pre-clinically, ERCC1 and XPF was depleted in A2780 (platinum sensitive) and A2780cis (platinum resistant) ovarian cancer cell lines and tested for platinum sensitivity as well as for Olaparib induced synthetic lethality. RESULTS: Low ERCC1 was significantly associated with improved progression free survival (PFS) in patients with ovarian cancers in univariate (p = 0.001) and multivariate (p = 0.002) analysis. In addition, low ERCC1/low XPF (p = 0.003) or low ERCC1/low PARP1 (p = 0.0001) tumors was also linked to better PFS compared to high ERCC1/high XPF or high ERCC1/high PARP1 tumors. Pre-clinically, ERCC1 or XPF depletion not only increased platinum sensitivity but also increased toxicity to Olaparib therapy. Increased sensitivity was associated with DNA double strand breaks (DSBs) accumulation, cell cycle arrest and increased apoptosis. CONCLUSION: The data provide evidence that low ERCC1 is not only a predictor of platinum sensitivity but is also a promising biomarker for Olaparib induced synthetic lethality in ovarian cancers.
引用
- Mesquita KA, Alabdullah M, Griffin M, et al. ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers. Gynecol Oncol. 2019. PMID: 30797591. doi:10.1016/j.ygyno.2019.02.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。